Pharvaris NV Director Glassman Bets Big: Sells 9,999 Shares at $29.83, Buys 5,333 at $22.31, and Sheds Options – Insider Signals Bullish Confidence Amid Surge in Share Price.

Insider Activity Snapshot – Pharvaris NV

On May 15, 2026, Pharvaris NV’s director Robert Glassman executed a mixed‑bag transaction: he purchased 5,333 shares of common stock at $22.31 while simultaneously selling 9,999 shares (5,333 + 4,667) at prices ranging from $29.82 to $29.83. He also liquidated 5,333 stock‑option rights at no cash consideration. The net effect leaves Glassman’s holding at 20,500 shares, a modest increase relative to his pre‑transaction balance of 15,167 shares.

What the Numbers Mean for Investors

The sale side of Glassman’s activity is priced above the current market level of $25.85, reflecting a modest upside that likely stems from a short‑term trading window rather than a fundamental reassessment. The purchase, however, is executed at a discount to the recent closing price, suggesting confidence in the company’s near‑term prospects. When combined with the concurrent option liquidations—typically a sign that an insider believes the shares will remain above the strike price—the pattern points to a bullish stance: Glassman is hedging short‑term exposure while locking in gains from options that have already appreciated.

Broader Insider Landscape

Pharvaris also witnessed a flurry of sales from other top executives on the same day. Chief Technical Ops Officer Stefan Abele sold 8,748 shares at $29.82; Chief Commercial Officer Wim Souverijns sold 10,000 shares at $29.92. These figures are consistent with the Rule 144 disclosures, indicating that the sales are part of a planned, compliant exit strategy rather than a sudden loss of confidence. The overall trend across the board shows insiders taking a modest position in cash while maintaining sizeable post‑sale holdings, which is typical in a clinical‑stage company that is still awaiting product milestones.

Implications for the Company’s Future

The insider activity aligns with Pharvaris’s recent stock‑price surge—up 13.6% in the week and 18.8% monthly—suggesting that the market has already priced in expectations of regulatory milestones or positive trial data. Glassman’s purchase, coupled with the option sales, signals that insiders remain optimistic about the company’s long‑term trajectory, especially given Pharvaris’s focus on novel B2 receptor antagonists that could capture a sizable niche in the health‑care market.

For investors, the key takeaway is that the insider actions do not indicate any impending distress. Instead, they reflect a strategic realignment of liquidity and risk: insiders are harvesting gains from a well‑performing share price while securing future upside through retained option exposure. This balanced approach can be reassuring for shareholders who seek both short‑term stability and long‑term growth potential in a clinical‑stage biotech environment.